BPC-157 Regulatory Status 2026: What Researchers Need to Know
Last Updated: July 8, 2026 | Reading Time: Approximately 7 minutes | Author: Palmetto Peptides Research Team
Quick Answer
As of 2026, BPC-157 is not approved by the FDA for any human or veterinary use and is not scheduled as a controlled substance by the DEA. It is legally sold as a research chemical for laboratory use. Selling BPC-157 with therapeutic claims, marketing it for human consumption, or selling it to be administered to humans is illegal under FDA regulations. Researchers purchasing BPC-157 for in vitro or animal model research are operating within the law when doing so through appropriately labeled research-use-only suppliers.
Research Notice: This article covers research on BPC-157 research peptide — available from Palmetto Peptides for laboratory use only.
Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.
Research Use Only: BPC-157 is not approved by the FDA for human consumption, therapeutic use, or veterinary applications. All research referenced in this article was conducted in animal models or in vitro systems. This compound is sold by Palmetto Peptides exclusively for licensed laboratory research.
FDA Classification and Approval Status
The U.S. Food and Drug Administration (FDA) regulates drugs, biologics, and medical devices. For a compound to be legally marketed for human therapeutic use in the United States, it must go through the FDA's new drug approval process — including Phase I, II, and III clinical trials demonstrating safety and efficacy for a specific indication.
BPC-157 has not undergone this process. It is not an FDA-approved drug. There is no IND (Investigational New Drug application) for BPC-157 known to be active in the FDA's public database as of 2026. BPC-157 cannot legally be sold, marketed, or administered with any therapeutic, medical, or health claims.
The FDA's authority applies to: marketing claims, labeling, sale of compounds intended for human use, and compounding by licensed pharmacies. Research-grade BPC-157 sold with clear "for research use only, not for human consumption" labeling falls outside the FDA's drug marketing authority — it is regulated more like a laboratory chemical than a pharmaceutical.
DEA Scheduling Status
The Drug Enforcement Administration (DEA) maintains schedules of controlled substances under the Controlled Substances Act (CSA). BPC-157 is not scheduled as a controlled substance under the CSA as of 2026. It is not a Schedule I, II, III, IV, or V substance.
This means BPC-157 can be purchased, possessed, and used for research without DEA registration in most circumstances. (Researchers working with scheduled substances in the same laboratory context may already have DEA registration for those compounds — BPC-157 does not require or benefit from this separately.)
The Research Use Exemption
U.S. law permits the purchase and use of non-approved substances for legitimate scientific research. This is how academic institutions, pharmaceutical companies, and independent researchers legally work with thousands of non-approved compounds annually in the drug discovery and preclinical research pipeline.
The key requirements for legal research use of BPC-157:
- Research-only purpose: The compound must be purchased and used for legitimate in vitro or animal model research, not for administration to humans.
- Appropriate supplier labeling: The supplier must label the product clearly as "for research use only" and "not for human consumption."
- No therapeutic claims: Neither the supplier nor the researcher should make therapeutic claims about the compound's effects in humans.
- Institutional compliance: Academic and institutional researchers should ensure their use complies with their IRB or IACUC protocols as appropriate.
Compounding Pharmacy Restrictions
A separate but related regulatory question involves whether BPC-157 can be compounded by licensed pharmacies under FDA's 503A (patient-specific) or 503B (outsourcing facility) pathways.
The FDA has published guidance lists of substances that cannot be included in compounded preparations. The regulatory status of BPC-157 in this compounding context has been evolving, with FDA periodically updating its lists of substances under evaluation. Researchers and practitioners working in compounding contexts should consult current FDA guidance for the most up-to-date compounding status, as this is distinct from research-use regulations.
Palmetto Peptides sells BPC-157 exclusively as a research chemical — not as a compounded preparation and not for clinical use.
State Law Considerations
While federal law governs FDA drug approval and DEA scheduling, individual states may have additional regulations affecting research chemical distribution or use. Most states follow federal guidelines without additional restrictions on research chemicals. However, researchers in regulated professional contexts (physicians, pharmacists, veterinarians) should be aware that their professional licensing boards may have separate positions on non-approved compounds.
Practical Compliance for Researchers
For independent and institutional researchers working with BPC-157:
- Purchase from research-only suppliers with appropriate labeling — not from sources marketing it for human use
- Maintain documentation of purchase receipts, COAs, and research protocols
- Use only in laboratory settings for animal model or in vitro research
- Do not administer to humans — this violates FDA regulations regardless of whether the compound is scheduled
- Do not make therapeutic claims about research findings before going through the appropriate clinical trial pathway
Palmetto Peptides maintains full regulatory compliance by selling BPC-157 with research-use-only labeling, providing batch-specific COAs, and not making any therapeutic claims. Our products are intended for licensed laboratory research only.
Research products: BPC-157 (5mg / 10mg) | BPC-157 + TB-500 Wolverine Stack